Biosimilars Access and Affordability Act modifies Medicare eligibility for biosimilar biological products.
The Biosimilars Access and Affordability Act amends the Social Security Act to change when biosimilar biological products are eligible for price negotiations under the Medicare program. It introduces a two-year delay for biosimilars to be included in the list of selected drugs for price negotiations. The bill also mandates that the Secretary of Health and Human Services inform manufacturers of biosimilar biological products of the information relied upon for eligibility determinations and requires manufacturers to confirm the accuracy of this information.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.